<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Immunologic transfusion reactions</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Immunologic transfusion reactions</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Immunologic transfusion reactions</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aaron Tobian, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven Kleinman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Transfusions can be lifesaving for patients with severe anemia, thrombocytopenia, or deficiency of plasma components. In general, transfusions are safe. However, allogenic blood cells and plasma proteins are foreign substances that can elicit an immune response in the recipient, and plasma contains antibodies and other immune mediators that can react with recipient cells. As a result, transfusion carries risks of immunologic reactions.</p><p>This topic review discusses common immunologic transfusion reactions. Other types of transfusion reactions, and the approach to the patient with a suspected transfusion reaction for which the cause is unknown, are discussed in separate topic reviews.</p><p class="bulletIndent1"><span class="glyph">●</span>Transfusion reaction of unknown cause – (See  <a class="medical medical_review" href="/d/html/95132.html" rel="external">"Approach to the patient with a suspected acute transfusion reaction"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Hemolytic transfusion reactions (HTR) – (See  <a class="medical medical_review" href="/d/html/7932.html" rel="external">"Hemolytic transfusion reactions"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Transfusion-related acute lung injury (TRALI) – (See  <a class="medical medical_review" href="/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Transfusion-associated circulatory overload (TACO) – (See  <a class="medical medical_review" href="/d/html/7919.html" rel="external">"Transfusion-associated circulatory overload (TACO)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis – (See  <a class="medical medical_review" href="/d/html/3805.html" rel="external">"Transfusion-transmitted bacterial infection"</a>.)</p><p></p><p class="headingAnchor" id="H1591342727"><span class="h1">DISTINGUISHING AMONG IMMUNOLOGIC REACTIONS</span><span class="headingEndMark"> — </span>Many of the acute immunologic reactions discussed below can present with fever and/or respiratory symptoms, making it challenging to distinguish them from each other in the initial stages. </p><p class="bulletIndent1"><span class="glyph">●</span>Distinguishing findings are listed in the table  (<a class="graphic graphic_table graphicRef94399" href="/d/graphic/94399.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An overview of our approach to the evaluation and immediate interventions is presented in the algorithm  (<a class="graphic graphic_algorithm graphicRef96323" href="/d/graphic/96323.html" rel="external">algorithm 1</a>); these include stopping the transfusion, maintaining a patent intravenous line, and confirming the correct product for the patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specific testing based on the initial patient symptoms is presented in detail separately. (See  <a class="medical medical_review" href="/d/html/95132.html" rel="external">"Approach to the patient with a suspected acute transfusion reaction"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">FEBRILE NONHEMOLYTIC TRANSFUSION REACTIONS</span></p><p class="headingAnchor" id="H1596046555"><span class="h2">Definition of FNHTR</span><span class="headingEndMark"> — </span>The United States Centers for Disease Control and Prevention (CDC) Biovigilance Network revised the criteria for febrile nonhemolytic transfusion reaction (FNHTR) in 2021 with the following definition [<a href="#rid1">1</a>]: </p><p>Definitive FNHTR is a reaction that occurs within four hours of transfusion termination and for which no other conditions could explain the signs or symptoms of either:</p><p class="bulletIndent1"><span class="glyph">●</span>A fever of &gt;38°C with an accompanying temperature increase of &gt;1°C</p><p></p><p class="bulletIndent1">or-</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chills/rigors</p><p></p><p class="headingAnchor" id="H2797940480"><span class="h2">Prevalence of FNHTR</span><span class="headingEndMark"> — </span>FNHTRs are among the most common of all transfusion reactions. Approximately 1 percent of all transfusions are associated with an otherwise unexplained rise in temperature of at least 1°C, with or without chills and rigors [<a href="#rid2">2-4</a>]. </p><p>FNHTRs are not serious, as the fever responds to antipyretics and the rigors to <a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">meperidine</a>. However, these reactions are discomforting for the patient and ultimately quite expensive, since they require that an infectious etiology be excluded and, in many cases, that an additional unit of blood be crossmatched and transfused. In some patients (eg, asplenia due to sickle cell disease), development of fever may necessitate hospitalization and empiric antibiotic therapy until an infectious etiology is eliminated [<a href="#rid2">2,3,5</a>].</p><p>The following factors affect the likelihood of an FNHTR: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient age</strong> – FNHTRs are more frequent in children than adults. In a 2015 study involving over 100,000 transfusions, the rate of FNHTR was 0.2 percent per transfusion in children and 0.05 percent in adults [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood product</strong> – FNHTRs can occur with any product; overall, they are equally likely from platelets and red blood cells (RBCs), and more likely with either of these cellular products than with plasma products  (<a class="graphic graphic_table graphicRef94399" href="/d/graphic/94399.html" rel="external">table 1</a>). They are most likely with platelets prepared from platelet-rich plasma (ie, whole blood-derived platelets, as opposed to apheresis platelets), since these platelet products have the highest concentration of leukocytes (white blood cells [WBCs]) [<a href="#rid7">7,8</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukoreduction</strong> – FNHTRs are much less likely if the product has undergone prestorage leukoreduction (removal of WBCs). Bedside leukoreduction may slightly decrease the risk, but pre-storage leukoreduction is more effective [<a href="#rid9">9</a>].</p><p></p><p>A re-analysis of data from the original article about FNHTRs in 1962 indicated that 40 percent of patients experiencing an FNHTR will experience a subsequent FNHTR, with 24 percent having a recurrent FNHTR on the very next transfusion [<a href="#rid10">10,11</a>]. </p><p class="headingAnchor" id="H1933432"><span class="h2">Mechanism of FNHTR</span><span class="headingEndMark"> — </span>FNHTRs appear to be mediated both by donor leukocytes (WBCs) and by generation and accumulation of cytokines that occur during the storage of blood components and after transfusion [<a href="#rid12">12-18</a>]. It has been proposed that an interaction between donor leukocytes and recipient antibodies leads to interleukin (IL)-1 release from donor leukocytes or recipient monocytes. IL-1 produces fever by stimulating prostaglandin E2 (PGE2) production in the hypothalamus. Other implicated cytokines include IL-6, IL-8, and tumor necrosis factor-alpha (TNFα). </p><p>Cytokine accumulation during storage may play a primary role. The risk of a transfusion reaction has been demonstrated to increase with the age of the unit transfused [<a href="#rid13">13</a>]. Removal of plasma is more effective than post-storage leukoreduction in preventing reactions, especially severe reactions to platelets [<a href="#rid19">19,20</a>].</p><p>The role of leukocytes in the stored product as a potential source of cytokines was illustrated in the Trial to Reduce Alloimmunization to Platelets (TRAP), in which FNHTRs were significantly associated with products containing more than 5 x 10<sup>6</sup> leukocytes per transfusion and with components stored for more than 48 hours [<a href="#rid21">21</a>].</p><p>The relative importance of cytokines rather than the leukocytes themselves was illustrated in a study in which 64 platelet concentrates were separated into cellular and plasma components, and then these were transfused into 12 volunteers in random order [<a href="#rid22">22</a>]. There were 20 reactions to the plasma supernatant, six reactions to the cells, and eight reactions to both products. There was a strong correlation between FNHTRs and the concentrations of IL-1 and IL-6 in the plasma. Cytokines can be released from leukocytes that were not removed prior to storage of the blood product (ie, products that did not undergo pre-storage leukoreduction), which explains the greater benefit of pre-storage leukoreduction in reducing the risk of FNHTR compared with bedside leukoreduction. (See  <a class="medical medical_review" href="/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Pre-storage leukoreduction'</a>.)</p><p>The importance of the duration of product storage in cytokine accumulation has been demonstrated in several studies. As an example, in a series that evaluated reactions to 117 red blood cell transfusions and 65 platelet transfusions, the dominant factors determining the risk of a reaction were a longer duration of product storage and a higher number of leukocytes in the product [<a href="#rid13">13</a>]. In another report, the mean IL-8 concentration increased 100-fold between days 2 and 5 of storage and rose further with continued storage [<a href="#rid14">14</a>]. </p><p>Alternative mechanisms for FNHTR reactions have been proposed:</p><p class="bulletIndent1"><span class="glyph">●</span>FNHTRs have been associated with antibodies directed against class I HLA antigens present on leukocytes in red cell concentrates, or, less commonly, antibodies to platelet or granulocyte antigens [<a href="#rid12">12,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FNHTRs accompanying platelet transfusions have also been associated with release of platelet-derived CD154 (CD40 ligand), which is capable of inducing production of proinflammatory cytokines from fibroblasts, epithelial cells, and endothelial cells [<a href="#rid24">24-27</a>].</p><p></p><p class="headingAnchor" id="H5851821"><span class="h2">Clinical presentation and diagnosis of FNHTR</span><span class="headingEndMark"> — </span>Clinical manifestations of FNHTR occur within one to six hours after initiation of a transfusion and within four hours of transfusion termination [<a href="#rid1">1</a>]. These include fever, often a chill, occasionally severe rigors (most often seen with, though not restricted to, granulocyte transfusions), and sometimes mild dyspnea  (<a class="graphic graphic_table graphicRef94399" href="/d/graphic/94399.html" rel="external">table 1</a>)</p><p>FNHTRs are diagnosed clinically by excluding other causes of fever in a patient receiving a transfusion  (<a class="graphic graphic_algorithm graphicRef96323" href="/d/graphic/96323.html" rel="external">algorithm 1</a>). There is no laboratory or other testing that can confirm or exclude the presence of a FNHTR. The extent of the evaluation for other causes depends on the severity of the temperature increase and the presence or absence of other symptoms. As an example, a patient with fever, hypotension, and back pain should have a full evaluation for hemolytic transfusion reaction and possibly sepsis, whereas an individual with isolated mild fever may have a physical examination, clerical check of the transfusion, and visual inspection of the blood product. It is important that febrile reactions always be reported to the transfusion medicine service or blood bank, since it is almost impossible to distinguish more severe reactions without transfusion service laboratory evaluation. </p><p class="bulletIndent1"><span class="glyph">●</span>Other transfusion reactions associated with fever include acute hemolytic transfusion reaction (AHTR) and sepsis. Unlike FNHTRs, individuals with acute hemolysis are often acutely ill and have free hemoglobin in blood and urine or red or dark colored serum and urine. Unlike FNHTRs, individuals with sepsis are often acutely ill with positive blood cultures. In contrast, individuals with FNHTRs are generally not that ill and do not have these other abnormal findings. Both acute hemolysis and sepsis can also be associated with disseminated intravascular coagulation, which is not seen with FNHTRs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transfusion reactions associated with dyspnea include transfusion-associated circulatory overload (TACO), transfusion-related acute lung injury (TRALI) and anaphylactic reactions. Dyspnea is a major finding in these reactions, whereas it is generally mild or absent in a FNHTR. Unlike FNHTRs, individuals with TACO and TRALI have evidence of pulmonary edema on physical examination and chest radiography, and individuals with anaphylactic reactions have wheezing and sometimes other findings such as hypotension or angioedema.</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Management of FNHTR</span><span class="headingEndMark"> — </span>FNHTRs are benign, causing no lasting sequelae, but they are uncomfortable and sometimes frightening to the patient. Furthermore, since fever may be the sign of an acute hemolytic transfusion reaction or infection, FNHTRs require action on the part of the clinical team. This typically involves the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Stop the transfusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer antipyretics if the fever is bothersome to the patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate for other causes of fever, which include more serious (and potentially life-threatening) transfusion reactions as well as non-transfusion-related infection or fever, which may be due to the patient's underlying disorder. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Admit to the hospital (if the transfusion is administered in an out-patient setting) for presumptive treatment of infection, if this is considered to have high enough likelihood (eg, in a patient with functional asplenia from sickle cell disease). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer other medications if needed, such as <a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">meperidine</a> (25 to 50 mg) for severe chills or rigors. </p><p></p><p class="headingAnchor" id="H1934216"><span class="h2">Prevention of FNHTR</span><span class="headingEndMark"> — </span>Regardless of the etiology, FNHTRs can be minimized by reducing the number of leukocytes (WBCs) transfused [<a href="#rid28">28</a>]. Each unit of whole blood or unmodified RBCs contains approximately 2 to 5 x 10<sup>9</sup> leukocytes. FNHTRs can be largely eliminated if the total leukocyte count is reduced by one to two logs (90 to 99 percent), to &lt;5 x 10<sup>8</sup> [<a href="#rid15">15</a>]. </p><p>We do <strong>not</strong> use premedications (<a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> or <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>) to decrease the incidence of FNHTRs, as these medications are ineffective in preventing reactions and may cause adverse events on their own such as cardiovascular symptoms and central nervous system alterations. This lack of benefit was highlighted in a 2019 meta-analysis that evaluated the rates of FNHTR with premedication versus placebo or no treatment; no benefit was seen with premedication [<a href="#rid29">29</a>]. All blood products used in the trials in the meta-analysis were leukoreduced. Nonhemolytic reactions occurring within four hours of transfusion were seen in approximately one-fifth of patients (approximately 2.5 percent of transfusions), regardless of whether the patient received premedication with diphenhydramine and acetaminophen. Individuals who received premedication had a slightly higher rate of FNHTRs and a slightly lower rate of minor allergic reactions, neither of which reached statistical significance. An earlier review came to similar conclusions regarding the lack of efficacy of premedication [<a href="#rid30">30</a>].</p><p>Use of high quality leukocyte reduction filters is the most common method to achieve effective leukoreduction. Other methods to achieve sufficient leukocyte reduction include <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> washing, freezing and deglycerolizing, buffy coat removal, and microaggregate ("second-generation") filters. The most effective leukocyte reduction filters ("third-generation") can achieve a three- to four-log (99.9 to 99.99 percent) reduction in leukocytes, leaving residual leukocyte counts &lt;5 x 10<sup>6</sup> and generally &lt;1 x 10<sup>6</sup> [<a href="#rid16">16,17</a>]. </p><p>The US Food and Drug Administration (FDA) regulations for the quality of "leukocytes reduced" blood products require that components contain &lt;5 x 10<sup>6</sup> WBCs per unit [<a href="#rid31">31</a>]. An FDA guideline affirming this criterion was published in 2012 [<a href="#rid32">32</a>]. The European Community standard has been set at &lt;1 x 10<sup>6</sup> WBCs per unit [<a href="#rid17">17</a>]. In a multicenter study of the effectiveness of leukoreduction techniques, more than 99 percent of leukoreduced units met the United States standards and more than 91 percent of leukoreduced units met the European Community standard [<a href="#rid17">17</a>].</p><p>Randomized trials of leukocyte reduction for prevention of FNHTR are scarce [<a href="#rid18">18,33</a>]. </p><p>Three large retrospective cohort studies compared the frequency of acute reactions to RBCs and platelets before and after universal leukoreduction (ie, 100 percent of a particular blood component [eg, RBC units] undergo leukoreduction) had been implemented [<a href="#rid9">9,34,35</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The frequency of FNHTRs to RBCs was 0.33 to 0.37 percent prior to leukoreduction and was reduced to 0.15 to 0.19 percent following universal leukoreduction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The frequency of FNHTRs to platelets was 0.45 to 2.18 percent prior to leukoreduction and was reduced to 0.11 to 0.15 percent following universal leukoreduction.</p><p></p><p>There is no evidence that pathogen inactivation (or pathogen reduction technology [PRT]) has any impact on the incidence of FNHTRs, despite its profound effect on WBC function, as neutrophils subjected to PRT can still leak cytokines during storage. (See  <a class="medical medical_review" href="/d/html/7929.html" rel="external">"Pathogen inactivation of blood products"</a>.)</p><p class="headingAnchor" id="H1384219212"><span class="h1">ALLERGIC REACTIONS</span></p><p class="headingAnchor" id="H2977632009"><span class="h2">Prevalence and mechanisms of allergic reactions</span><span class="headingEndMark"> — </span>Allergic reactions, characterized by itching and hives, are one of the most common transfusion reactions, although the true prevalence is unknown because these are likely to be underreported [<a href="#rid36">36</a>]. They are seen in as many as 1 to 3 percent of recipients of platelet and plasma components and 0.1 to 0.3 percent of recipients of red blood cell (RBC) components [<a href="#rid4">4,30,37-39</a>]. </p><p>Allergic transfusion reactions are a type 1 hypersensitivity reaction that occurs when a soluble substance in the plasma of the donated blood product (or the recipient) reacts with preexisting IgE antibodies in the recipient (or the product), respectively. Allergic reactions are thought to be due to mast cell or basophil release of histamine, although other mechanisms may be involved. (See  <a class="medical medical_review" href="/d/html/8101.html" rel="external">"New-onset urticaria"</a>.) </p><p>Allergic reactions are multifactorial and often involve donor, product, and recipient factors. </p><p class="bulletIndent1"><span class="glyph">●</span>Plasma proteins are a common etiology. Recipients may be predisposed to a specific allergen with high IgE levels and react to the blood product that contains that allergen [<a href="#rid40">40</a>]. Alternatively, there have also been case reports of a donor with a peanut allergy and high levels of IgE to peanuts triggering an allergic reaction after receiving a transfusion from a recipient who had ingested peanuts [<a href="#rid38">38,41-43</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Non-antibody mechanisms are also important [<a href="#rid39">39</a>]. As an example, a study compared inflammatory mediators in 20 apheresis platelet products associated with allergic transfusion reactions versus apheresis platelet products that did not cause allergic reactions [<a href="#rid44">44</a>]. The platelet products associated with allergic transfusion reactions had higher levels of the direct allergic agonists than the control platelet products (C5a, 17 percent higher; brain-derived neurotrophic factor [BDNF], 42 percent higher; CCL5 [RANTES], 14 percent higher) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to donor and product factors, recipient factors play a critical role. This was illustrated in a study of different recipients who received a transfusion from the same donor and did not have the same reaction. Generally, two or three apheresis platelet units are produced from the same donor during one collection (split apheresis platelet products). In a study of 1616 allergic reactions among 93,737 recipients of split apheresis platelet products in which split apheresis platelet units from the same donor were transfused to at least two different recipients, an allergic reaction in one recipient was not associated with an increased risk of an allergic reaction in the other recipients [<a href="#rid45">45</a>].</p><p></p><p>The major difference between allergic reactions and anaphylactic reactions is of degree; allergic reactions are mild, whereas anaphylactic reactions are associated with massive release of histamine and other mediators. It is unknown whether certain mediators are specific for anaphylaxis. (See <a class="local">'Anaphylactic transfusion reactions'</a> below.)</p><p class="headingAnchor" id="H4076986693"><span class="h2">Clinical presentation and diagnosis of allergic reactions</span><span class="headingEndMark"> — </span>Allergic reactions present with pruritus, hives or urticaria, or localized angioedema, which can occur during, at the end, or shortly after a transfusion. No other allergic findings are present (there is no wheezing or systemic angioedema). This timing slightly differs from anaphylactic reactions, which typically occur within minutes of starting a transfusion. (See <a class="local">'Clinical presentation and diagnosis of anaphylactic reactions'</a> below.)</p><p>Criteria from the United States Centers for Disease Control and Prevention (CDC) Biovigilance Network define allergic transfusion reactions as definitive if the patient has at least two symptoms within four hours after the completion of the transfusion [<a href="#rid1">1</a>].</p><p>Minor allergic reactions are diagnosed clinically when a patient develops itching, hives, localized erythema or edema, or a maculopapular rash without progression to more severe symptoms that suggest an anaphylactic reaction. (See <a class="local">'Clinical presentation and diagnosis of anaphylactic reactions'</a> below.)</p><p>Improvement of the allergic symptoms with stopping the transfusion and administration of <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> is strongly supportive of an allergic rather than an anaphylactic reaction. (See <a class="local">'Management of allergic reactions'</a> below.)</p><p>Rarely, an allergic reaction may be the first sign of a more serious reaction. If there is evidence of hypotension or respiratory distress, the possibility of anaphylaxis should be evaluated urgently. (See <a class="local">'Clinical presentation and diagnosis of anaphylactic reactions'</a> below.)</p><p>For patients who have recurrent allergic reactions, further evaluation for specific substances to which the patient is allergic may be performed (allergy testing). (See  <a class="medical medical_review" href="/d/html/5541.html" rel="external">"Overview of skin testing for IgE-mediated allergic disease"</a> and  <a class="medical medical_review" href="/d/html/2396.html" rel="external">"Diagnostic evaluation of IgE-mediated food allergy"</a>.)</p><p class="headingAnchor" id="H895092904"><span class="h2">Management of allergic reactions</span><span class="headingEndMark"> — </span>Allergic transfusion reactions are one of the few transfusion reactions in which the remainder of the blood product can be administered. However, before this is done, the transfusion should first be stopped, and, if the hives and urticaria are extensive, 25 to 50 mg of <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> can be given orally or intravenously. </p><p class="bulletIndent1"><span class="glyph">●</span>If the hives/urticaria wane and there is no evidence of dyspnea, hypotension, or anaphylaxis, the transfusion may be resumed.</p><p class="bulletIndent1"><span class="glyph">●</span>If the hives/urticaria persist, additional doses of <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> (and/or other symptomatic therapies) can be administered.</p><p></p><p>Data supporting treatments other than <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> are limited. However, more serve allergic reactions or those refractory to diphenhydramine can be treated with <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> (20 mg intravenously), <a class="drug drug_general" data-topicid="8544" href="/d/drug information/8544.html" rel="external">hydroxyzine</a> (50 mg orally), or solumedrol (125 mg intravenously). </p><p class="headingAnchor" id="H1148164845"><span class="h2">Prevention of allergic reactions</span><span class="headingEndMark"> — </span>Several studies have demonstrated that product manipulation to decrease the amount of plasma can reduce allergic transfusion reactions. </p><p class="bulletIndent1"><span class="glyph">●</span>Studies have demonstrated that transfusing platelets stored in platelet additive solution rather than plasma decreased minor allergic reactions by 46 percent and was cost-effective for patients with recurrent allergic reactions [<a href="#rid46">46,47</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional small studies suggested that allergic reactions to platelets could be decreased by platelet washing (pooled whole blood-derived and apheresis platelets) [<a href="#rid48">48,49</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective cohort study of 179 individuals who first received unmanipulated platelets and subsequently received platelets from which plasma had been removed found a decline in allergic transfusion reactions from 5.5 percent for unmanipulated platelets to 1.7 percent for concentrated platelets and 0.5 percent for washed platelets [<a href="#rid50">50</a>]. </p><p></p><p>However, concentrating and washing platelet products decreases the number of viable platelets in the transfusion and may necessitate additional transfusions in some cases [<a href="#rid51">51</a>]. </p><p>Concentrating or washing should only be used for patients who experience severe or repeated allergic reactions that cannot otherwise be prevented. It is appropriate to try concentrating the blood component (either RBCs or platelets) first and only washing the cells if plasma removal by concentration does not prevent the allergic reactions. </p><p>Similar to FNHTR, we do <strong>not</strong> recommend the use of premedications (<a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> and/or <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>) to decrease the incidence of allergic reactions, as they are ineffective and may cause adverse events such as drowsiness. A systematic review of three randomized control trials demonstrated there is no clinical benefit of antihistamine premedication [<a href="#rid30">30,52-55</a>]. (See <a class="local">'Prevention of FNHTR'</a> above.)</p><p class="headingAnchor" id="H13"><span class="h1">ANAPHYLACTIC TRANSFUSION REACTIONS</span></p><p class="headingAnchor" id="H1664430507"><span class="h2">Prevalence and mechanisms of anaphylactic reactions</span><span class="headingEndMark"> — </span>Anaphylactic transfusion reactions are a severe form of allergic reactions and are rare, with an estimated incidence of 1 in 20,000 to 1 in 50,000 per unit transfused [<a href="#rid4">4,56,57</a>]. </p><p>Anaphylaxis results from sudden (typically massive) systemic release of mediators such as histamine and tryptase by mast cells and basophils, typically in response to an IgE-mediated (or IgG-mediated) immune reaction. (See  <a class="medical medical_review" href="/d/html/386.html" rel="external">"Pathophysiology of anaphylaxis"</a>.)</p><p>Anaphylaxis can occur with transfusion of red blood cells (RBCs), platelets, granulocytes, or plasma products (eg, Fresh Frozen Plasma [FFP], Cryoprecipitate, or intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> [IVIG]). These reactions are not seen with plasma derivatives (albumin, purified clotting factors). Typically, the reaction occurs because the transfused product contains a substance to which the recipient is allergic; the converse has also been reported (ie, the reaction occurs because the transfused product contains IgE that reacts with a substance in the recipient).</p><p>Several specific mechanisms and the clinical settings in which they occur have been described:</p><p class="bulletIndent1"><span class="glyph">●</span>A well-characterized mechanism is class-specific IgG anti-IgA antibodies in patients who are IgA deficient. Selective IgA deficiency is common, occurring in approximately 1 in 300 to 500 people. However, few IgA-deficient patients develop anti-IgA antibodies (eg, 1 in 1200 to 1600 IgA-deficient patients have anti-IgA antibodies). (See  <a class="medical medical_review" href="/d/html/3936.html" rel="external">"Selective IgA deficiency: Management and prognosis", section on 'Reactions to blood products'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anaphylaxis has been described after blood product transfusion in patients with anhaptoglobinemia (ie, congenital deficiency of haptoglobin) who develop anti-haptoglobin antibodies; this disorder primarily occurs in individuals from East Asia [<a href="#rid58">58,59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe laryngeal edema or bronchospasm can occur in recipients of plasma exchange, occurring in 1 in every 500 to 1000 plasma exchanges in some studies [<a href="#rid60">60,61</a>]. Some of these reactions may be due to hypersensitivity to ethylene oxide or other substances used to sterilize components of the apheresis kit [<a href="#rid62">62</a>]. Anaphylaxis to <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a>, used as a pathogen inactivation agent, has also been reported, although this is not likely to be a common cause of anaphylaxis [<a href="#rid37">37</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A blood donor was found whose transfused blood components (platelets) were implicated in two cases of anaphylactic transfusion reaction in 2002. The donor plasma showed mast cell degranulation activity due to the presence of high molecular weight (dimeric and trimeric) IgEs that likely directly activated the recipient's mast cells by crosslinking the immunoglobulin FC-epsilon receptor 1 [<a href="#rid63">63</a>]. The donor was ultimately diagnosed as having IgE kappa multiple myeloma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Case reports have described anaphylactic reactions due to passive transfer of a peanut allergen ingested by the blood donor and transfused into a child with a prior anaphylactic reaction to peanuts [<a href="#rid64">64,65</a>]. </p><p></p><p class="headingAnchor" id="H7642364"><span class="h2">Clinical presentation and diagnosis of anaphylactic reactions</span><span class="headingEndMark"> — </span>Anaphylactic transfusion reactions are of rapid onset (as are all anaphylactic reactions), typically occurring within a few seconds to a few minutes following initiation of a transfusion. The patient may experience shock, hypotension, angioedema, respiratory distress, and/or wheezing. These may or may not be preceded or accompanied by symptoms commonly described in allergic transfusion reactions including pruritus, urticaria, and flushing. (See <a class="local">'Clinical presentation and diagnosis of allergic reactions'</a> above.)</p><p>The diagnosis of an anaphylactic transfusion reaction is made clinically based on the timing of the reaction, rapid progression to potentially life-threatening symptomatology, and rapid response to therapy. </p><p>The differential diagnosis of an anaphylactic transfusion reaction includes other causes of dyspnea and hypotension during a transfusion (eg, transfusion-related acute lung injury [TRALI], transfusion-associated circulatory overload [TACO], sepsis), as well as other, non-transfusion-related allergic conditions (eg, asthma, drug allergy). Unlike anaphylactic reactions, these other reactions (TRALI, TACO, and sepsis) are generally not associated with wheezing and angioedema, and they do not resolve rapidly with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>.</p><p>The evaluation should not delay prompt/emergency treatment. (See <a class="local">'Treatment of anaphylactic reactions'</a> below.)</p><p>The typical evaluation of a patient with a moderate to severe anaphylactic reaction, almost always performed after the acute situation has been treated and symptoms resolved, involves quantitative measuring of IgA levels as well as anti-IgA (if indicated), preferably on a pre-transfusion sample. Mast cell tryptase can be measured if the test is available with a reasonable turnaround time, but the results generally do not alter diagnosis or management when the clinical diagnosis appears obvious. Chest imaging may help distinguish between pulmonary edema and bronchospasm if these cannot be differentiated clinically.</p><p class="headingAnchor" id="H14"><span class="h2">Treatment of anaphylactic reactions</span><span class="headingEndMark"> — </span>Anaphylactic reactions are frightening and potentially life-threatening. The initial assessment and emergency management of anaphylaxis is presented in the tables for adults  (<a class="graphic graphic_table graphicRef58346" href="/d/graphic/58346.html" rel="external">table 2</a>) and children  (<a class="graphic graphic_table graphicRef74242" href="/d/graphic/74242.html" rel="external">table 3</a>). Additional details of treatment are discussed separately. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.) </p><p>Major interventions include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Immediately stop the transfusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Give intramuscular <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, preferably to the mid-outer thigh, 0.01 mg/kg (maximum 0.5 mg) which requires use of a <strong>1 mg/mL solution</strong>. The dose may be repeated every 5 to 15 minutes (or more frequently) if needed. In some countries other than the United States, 1 mg/mL solution may be labeled as 1:1000.</p><p></p><p class="bulletIndent1">In many settings use of an autoinjector may be preferred; dosing is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients &gt;25 kg – 0.3 mg</p><p class="bulletIndent2"><span class="glyph">•</span>Infants and children 10 to 25 kg – 0.15 mg</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> should not be withheld due to concerns with bleeding due to a bleeding disorder or thrombocytopenia; the potential lifesaving benefit outweighs the small potential risk of intramuscular bleeding [<a href="#rid66">66</a>]. </p><p></p><p>In severe cases such as impending cardiovascular collapse refractory to intramuscular <a class="external" href="%2Fcontents%2Fepinephrine-adrenaline-drug-information%3Fsearch%3DReaction%2Bto%2Bblood%2Btransfusion%26topicRef%3D95132%26source%3Dsee_link&amp;data=05|01|Jonathan.Zand%40wolterskluwer.com|e445a536ac2541910c5108da2638efec|8ac76c91e7f141ffa89c3553b2da2c17|0|0|637864323247787183|Unknown|TWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D|3000|||&amp;sdata=cwaSaD6F0F1KlimQH2qbQ7P7jpWP6ulJ94p48StDlEI%3D&amp;reserved=0" target="_blank">epinephrine</a> and volume resuscitation, a slow intravenous bolus of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> is indicated, ideally with hemodynamic monitoring while an epinephrine infusion is prepared. In adults, the intravenous epinephrine dose is 0.05 to 0.1 mg, which requires 0.5 to 1 mL of a 0.1 mg/mL solution; this preparation is typically stocked on resuscitation carts as a syringe (1 mg epinephrine in 10 mL). In some countries other than the United States, the 0.1 mg/mL solution may be labeled as 1:10,000.</p><p class="bulletIndent1"><span class="glyph">●</span>For hypotension, use intravenous fluid resuscitation usually with normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>. Some patients may require a second vasopressor (in addition to <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> infusion). All vasopressors should be given by infusion pump, with the doses titrated continuously according to blood pressure and cardiac rate/function and oxygenation monitored by pulse oximetry.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maintain the airway and provide oxygen if needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For severe bronchospasm, inhaled bronchodilators, continuous positive airway pressure (CPAP), and/or an H2-antihistamine such as <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> may be appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For pruritus or angioedema, an H1-antihistamine (<a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a> or <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a>, 10 mg orally, or <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, 25 or 50 mg orally or intravenously) may also be administered. The diphenhydramine dose is at the discretion of the clinician treating the reaction and depends on the size of the individual and severity of the reaction. A repeat dose can be given 15 or 30 minutes after the first dose if needed for persistent itching or hives. The maximum dose of diphenhydramine is 100 mg in a one-hour period.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prepare for possible administration of an intravenous <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> drip if needed  (<a class="graphic graphic_table graphicRef75682" href="/d/graphic/75682.html" rel="external">table 4</a>).</p><p></p><p>Additional information is presented separately. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p class="headingAnchor" id="H2344266459"><span class="h2">Prevention of anaphylactic reactions</span><span class="headingEndMark"> — </span>Prevention of anaphylactic transfusion reactions consists of establishing the diagnosis after the fact and avoiding future exposures. </p><p>In general, it is best to avoid plasma transfusion in individuals with a previous anaphylactic transfusion reaction. If plasma is required and the patient is not IgA-deficient, allergic reactions may be less with solvent/detergent treated plasma (S/D plasma) [<a href="#rid67">67</a>]. Washing RBCs and platelet products also reduces the likelihood of allergic transfusion reactions [<a href="#rid50">50</a>].</p><p>If the previous anaphylactic transfusion reaction is proven to be due to anti-IgA antibodies, blood products from IgA-deficient donors may be used [<a href="#rid68">68-70</a>]. IgA-deficient blood products can be obtained through large regional blood centers. <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">Immune globulin</a> products such as intravenous immune globulin (IVIG) with low IgA levels are also available. (See  <a class="medical medical_review" href="/d/html/3936.html" rel="external">"Selective IgA deficiency: Management and prognosis", section on 'Safe administration of blood products'</a>.)</p><p class="headingAnchor" id="H1526217027"><span class="h1">HEMOLYTIC TRANSFUSION REACTIONS</span><span class="headingEndMark"> — </span>Hemolytic transfusion reactions (HTRs) are characterized by immune-mediated red blood cell (RBC) destruction (hemolysis). They can be acute (during or within 24 hours after a transfusion) or delayed (days to weeks after a transfusion); and the hemolysis can be intravascular (releasing free hemoglobin into the circulation) or extravascular (resulting in removal of RBCs by the reticuloendothelial system)  (<a class="graphic graphic_figure graphicRef111905" href="/d/graphic/111905.html" rel="external">figure 1</a>). </p><p>These reactions are reviewed briefly here and discussed in much greater detail separately. (See  <a class="medical medical_review" href="/d/html/7932.html" rel="external">"Hemolytic transfusion reactions"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>AHTR</strong> – Acute HTRs (AHTRs) are hemolytic reactions that occur during the transfusion or within 24 hours of completing the transfusion [<a href="#rid71">71</a>]. AHTRs are typically associated with rapid intravascular hemolysis, which can lead to acute kidney injury (AKI), disseminated intravascular coagulation (DIC), and hemodynamic collapse. The classic AHTR is a medical emergency requiring immediate intervention. Typical symptoms and findings include fever, chills, back or chest pain, and pink/red serum, plasma or urine, although the full "classic triad" of fever, flank pain, and red urine is rarely seen [<a href="#rid72">72</a>]. In a patient under anesthesia or in a coma, evidence of DIC (oozing from intravenous catheter sites) or hematuria may be the only findings. Additional laboratory evaluation will show evidence of hemolysis. </p><p></p><p class="bulletIndent1">AHTRs are most commonly seen in the setting of ABO blood group incompatibility due to a clerical or procedural error (transfusion of the wrong product); this will become apparent upon clerical check and laboratory testing. AHTR is a medical emergency. The initial steps are similar to those for any suspected acute transfusion reaction and include immediately stopping the transfusion, providing hemodynamic support, and contacting the transfusion service. </p><p></p><p class="bulletIndent1">Additional details of the pathophysiology, evaluation, and management of AHTR is presented separately. (See  <a class="medical medical_review" href="/d/html/7932.html" rel="external">"Hemolytic transfusion reactions", section on 'Acute hemolytic transfusion reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DHTR and DSTR</strong> – Delayed HTRs (DHTRs) are hemolytic reactions that occur more than 24 hours after completing the transfusion [<a href="#rid73">73</a>]. DHTRs are typically gradual and less severe. Laboratory findings may include a mild increase in anemia (or failure of the hemoglobin to increase as expected after transfusion) and evidence of extravascular hemolysis, which may include spherocytes on the peripheral blood smear. DHTRs almost always result from an anamnestic response following re-exposure to a foreign RBC antigen such as one from the Kidd or Rh system. Previous exposure may have occurred through transfusion or pregnancy. The Centers for Disease Control and Prevention (CDC) Biovigilance Network in the United States criteria for a DHTR require a positive DAT between 24 hours and 28 days after the transfusion, identification of the RBC antibody in the serum or eluate, and symptoms [<a href="#rid72">72</a>]. DHTRs generally do not require any treatment except for future avoidance of transfusions containing the implicated RBC antigen. If a DHTR is accompanied by more brisk hemolysis, more aggressive treatment may be required, similar to an AHTR. </p><p></p><p class="bulletIndent1">Delayed serologic transfusion reactions (DSTRs) are identical to DHTRs except that the patients are asymptomatic. DSTRs are diagnosed when the transfusion service laboratory detects a new clinically significant antibody on subsequent sample testing by either a positive DAT or a positive antibody screen [<a href="#rid72">72</a>]. </p><p></p><p class="bulletIndent1">DHTRs and DSTRs are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7932.html" rel="external">"Hemolytic transfusion reactions", section on 'Delayed hemolytic transfusion reactions and delayed serologic transfusion reactions'</a>.)</p><p></p><p class="headingAnchor" id="H3205349366"><span class="h1">TRANSFUSION-RELATED ACUTE LUNG INJURY</span><span class="headingEndMark"> — </span>Transfusion-related acute lung injury (TRALI) is a life-threatening form of acute lung injury that occurs when recipient neutrophils are activated by the transfused product (often due to either antibodies directed against HLA or neutrophils) in an appropriately primed pulmonary vasculature. Presenting findings include fever, chills, and respiratory distress. Therapy is largely supportive and may include intubation and mechanical ventilation. A subsequent evaluation is directed at identifying an implicated donor so that individual does not continue to donate due to the possible risk of TRALI in other recipients. (See  <a class="medical medical_review" href="/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)"</a>.)</p><p>An individual with previous TRALI can receive blood products from other donors without restrictions but should not receive any remaining untransfused portion of the implicated product or any other products from the implicated donor. </p><p class="headingAnchor" id="H18"><span class="h1">POST-TRANSFUSION PURPURA</span></p><p class="headingAnchor" id="H4084545437"><span class="h2">Prevalence and mechanisms of post-transfusion purpura</span><span class="headingEndMark"> — </span>Post-transfusion purpura (PTP) is an extremely rare transfusion reaction. Data are limited, but the incidence has been estimated to be approximately 1 in every 50,000 to 100,000 transfusions [<a href="#rid74">74</a>]. The United Kingdom Serious Hazards of Transfusion (SHOT) data document approximately one to three cases reported per year; this is a reduction from 9 to 11 cases per year prior to the implementation of universal leukoreduction [<a href="#rid75">75</a>]. </p><p>PTP occurs primarily in individuals sensitized to platelet antigens by exposure during pregnancy or transfusion; the female-to-male ratio is approximately 26:1 [<a href="#rid76">76,77</a>]. Red blood cells (RBCs) are most commonly implicated, but PTP can be seen with transfusion of any platelet-containing product, including RBCs, platelets, fresh (but not frozen) plasma, or granulocytes [<a href="#rid74">74,77</a>]. </p><p>PTP can be thought of as a delayed transfusion reaction involving platelets, in which an anamnestic response to a previously encountered foreign platelet antigen leads to an increase in production of anti-platelet antibodies by the recipient. The antigen most commonly implicated is the platelet antigen PlA1, now known as human platelet antigen 1a, (HPA-1a) [<a href="#rid78">78</a>]. Unlike a delayed hemolytic reaction, however, these antibodies cause destruction of both the PlA1-positive transfused platelets as well as bystander destruction of the patient's own PlA1-negative platelets, leading to thrombocytopenia. The mechanism by which the antibodies destroy the recipient's own platelets lacking the antigen is not well understood. Possibilities include adsorption of immune complexes onto the patient's own platelets, which are then destroyed, passive acquisition of the antigen from donor plasma, or elaboration of a new autoantibody to another platelet antigen. </p><p>Approximately 97 to 99 percent of individuals are PlA1 positive [<a href="#rid79">79</a>]. An individual lacking the antigen can be sensitized during pregnancy (ie, upon exposure to the antigen on fetal platelets) or by prior transfusion. Of note, PlA1 is also the antigen system most commonly implicated in neonatal alloimmune thrombocytopenia. (See  <a class="medical medical_review" href="/d/html/120653.html" rel="external">"Neonatal immune-mediated thrombocytopenia", section on 'Neonatal alloimmune thrombocytopenia'</a>.)</p><p>An alternative and even rarer syndrome leading to post-transfusion thrombocytopenia has been reported, in which the recipient of a plasma-containing blood product such as Fresh Frozen Plasma (FFP) develops severe thrombocytopenia, which may be accompanied by bleeding and an acute transfusion reaction, caused by the passive transfer of anti-platelet antibodies (eg, anti-HPA-1a/PlA1) from a previously immunized donor [<a href="#rid80">80</a>]. The time-course is much more rapid than PTP; thrombocytopenia due to passive antibody transfer occurs in hours rather than days, and recovery typically occurs within five days. Implicated donors are females with a history of pregnancy; these donors should be deferred from subsequent donations.</p><p class="headingAnchor" id="H104954893"><span class="h2">Clinical presentation and diagnosis of post-transfusion purpura</span><span class="headingEndMark"> — </span>Patients with PTP can present with severe thrombocytopenia (with platelet counts ≤20,000/microL), which is sufficient to cause purpura, petechiae, and clinically significant bleeding. For PTP caused by an alloantigen on the transfused platelets, the onset is approximately 5 to 10 days following transfusion, and the thrombocytopenia often lasts for days to weeks. For thrombocytopenia caused by passive transfer of an antiplatelet antibody, the onset is within hours, and recovery is within several days [<a href="#rid80">80</a>].</p><p>If a patient with unexplained thrombocytopenia has received a transfusion in the previous one to two weeks, efforts should be made to confirm or exclude the diagnosis of PTP. The diagnosis is confirmed by demonstrating a circulating alloantibody to a common platelet antigen, most often HPA-1a/PlA1, and lack of this antigen on the patient's own platelets [<a href="#rid81">81</a>]. However, specific tests to determine the platelet antigenic composition and/or the presence of anti-platelet antibodies may not be readily available, and it may be necessary to contact a specialty laboratory (such as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.versiti.org%2Fproducts-services%2Fhematology-testing&amp;token=sJHblGKj4RLNkjLHiHNtKtyUPnMKWnoVlFu%2B9cStf4Yl%2BZDNprfqvPnHJZdsR5JioptNEylpxenlqJgXKk3Oc68AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=7947" target="_blank">Versiti</a>) to obtain this testing [<a href="#rid82">82</a>]. </p><p>The differential diagnosis of PTP includes other immunologically mediated forms of thrombocytopenia, including immune thrombocytopenia (ITP), acquired autoimmune thrombotic thrombocytopenic purpura (TTP), and drug-induced thrombocytopenia. Like PTP, these conditions are associated with hallmarks of immune platelet destruction such as severe thrombocytopenia, occasional large platelets on the blood smear, and increased megakaryocytes in the bone marrow (if tested). Unlike PTP, these other thrombocytopenias rarely have a temporal relationship to a transfusion. (See  <a class="medical medical_review" href="/d/html/6676.html" rel="external">"Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6674.html" rel="external">"Drug-induced immune thrombocytopenia"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Treatment and prevention of PTP</span><span class="headingEndMark"> — </span>The preferred therapy for PTP is intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) in high doses (400 to 500 mg/kg per day), usually for five days; alternatively, 1 g/kg per day for two days can be given for severe thrombocytopenia [<a href="#rid83">83-85</a>]. It usually takes approximately four days for the platelet count to exceed 100,000/microL [<a href="#rid83">83,84</a>]. </p><p>High-dose glucocorticoids have been useful in some patients with PTP, as has exchange transfusion; however, both of these treatments take two or more weeks to act and have side effects (eg, alterations in blood glucose, infectious risk); therefore, these are not our preferred therapies. </p><p>HPA-1a/PlA1-negative patients diagnosed with PTP who require subsequent transfusion should receive blood products from an HPA-1a/PlA1-negative donor or RBCs that are washed to remove contaminating HPA-1a/PlA1-positive platelets [<a href="#rid86">86</a>]. </p><p>The transfusion of HPA-1a/PlA1-negative platelets is generally not effective during the acute episode, because most platelets (even antigen-negative platelets) are destroyed [<a href="#rid87">87</a>]. However, for patients who require a transfusion in the acute setting, avoidance of HPA-1a/PlA1-positive components is prudent because it will limit the exposure to immunogenic antigens and may prevent additional allosensitization.</p><p class="headingAnchor" id="H2281984819"><span class="h1">TRANSFUSION-RELATED IMMUNOMODULATION (TRIM)</span><span class="headingEndMark"> — </span>TRIM refers to the immunosuppressive activity of allogeneic blood, which has been evaluated since studies on kidney allograft survival were published in the 1970s. Increasing attention has been directed towards the impact of the immunosuppressive effect of allogeneic blood (particularly the leukocyte component) on postoperative infection, tumor recurrence, and nosocomial infection in critically ill patients [<a href="#rid88">88,89</a>]. The evidence that postoperative infection is increased in patients receiving allogeneic blood during surgery is compelling, though not absolute [<a href="#rid90">90-98</a>]. The same is true for the data implicating the leukocyte as the "culprit" [<a href="#rid97">97,99,100</a>]. </p><p>Several meta-analyses have been performed using slightly different approaches and have yielded conflicting results [<a href="#rid101">101-103</a>]. There is insufficient evidence to recommend routine use of leukocyte-depleted blood as a way to decrease the risk of postoperative infections. Other benefits of leukoreduction are presented separately. (See  <a class="medical medical_review" href="/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Pre-storage leukoreduction'</a>.)</p><p class="headingAnchor" id="H1092664760"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120167.html" rel="external">"Society guideline links: Transfusion and patient blood management"</a>.)</p><p class="headingAnchor" id="H10237461"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial steps</strong> – Many acute immunologic transfusion reactions can present with fever and/or respiratory symptoms. The table lists distinguishing findings  (<a class="graphic graphic_table graphicRef94399" href="/d/graphic/94399.html" rel="external">table 1</a>); the algorithm depicts initial evaluation and interventions  (<a class="graphic graphic_algorithm graphicRef96323" href="/d/graphic/96323.html" rel="external">algorithm 1</a>), including immediately stopping the transfusion and maintaining a patent intravenous line. (See  <a class="medical medical_review" href="/d/html/95132.html" rel="external">"Approach to the patient with a suspected acute transfusion reaction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FNHTRs</strong> – Febrile nonhemolytic transfusion reactions (FNHTRs) are caused by white blood cells or cytokines in the transfused product. FNHTRs typically present with fever and/or chills. The diagnosis is made clinically by excluding other causes of these symptoms. Management is supportive. Pre-storage leukoreduction reduces the risk of an FNHTR. We do <strong>not</strong> use premedications as they are ineffective and may cause adverse events. (See <a class="local">'Febrile nonhemolytic transfusion reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic reactions</strong> – Minor allergic reactions present with hives and/or urticaria without systemic manifestations. These reactions are quite common and are one of the few reactions in which the remainder of the blood product can be administered; this should only be done after the transfusion has been temporarily stopped and the reaction has resolved, with <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> if necessary. We do <strong>not</strong> use premedications. (See <a class="local">'Allergic reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anaphylactic reactions</strong> – Anaphylactic transfusion reactions are severe allergic reactions caused by sudden massive systemic release of mediators such as histamine and tryptase in response to an IgE (or IgG)-mediated immune response. They often occur within minutes of starting the transfusion and may present with wheezing, angioedema, and hypotension. These reactions are rare but potentially life-threatening and must be treated immediately, with stopping the transfusion, administering <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, and providing hemodynamic and respiratory support, as described for adults  (<a class="graphic graphic_table graphicRef58346" href="/d/graphic/58346.html" rel="external">table 2</a>) and children  (<a class="graphic graphic_table graphicRef74242" href="/d/graphic/74242.html" rel="external">table 3</a>). (See <a class="local">'Anaphylactic transfusion reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemolytic reactions</strong> – Hemolytic transfusion reactions (HTRs) involve immune-mediated hemolysis. They can be acute (AHTR; during or within 24 hours after transfusion) or delayed (DHTR; days to weeks after a transfusion). AHTRs are usually due to ABO incompatibility following a clerical/procedural error and are associated with intravascular hemolysis, which can be life-threatening. DHTRs are usually due to an anamnestic response to a previously encountered RBC antigen (through prior transfusion or pregnancy) and are often mild. Delayed serologic transfusion reactions (DSTRs) are similar to DHTRs except that the recipient is asymptomatic and the reaction is identified retrospectively during pretransfusion testing in the blood bank. The implicated RBC antigen should be avoided in future transfusions. (See <a class="local">'Hemolytic transfusion reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion-related acute lung injury</strong> — Transfusion-related acute lung injury (TRALI) is a life-threatening form of acute lung injury that occurs when recipient neutrophils are activated by the transfused product. Presenting findings include fever, chills, and respiratory distress. Therapy is largely supportive and may include intubation and mechanical ventilation. A subsequent evaluation is directed at identifying an implicated donor so that individual does not continue to donate due to the risk of TRALI in other recipients. (See  <a class="medical medical_review" href="/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-transfusion purpura</strong> – Post-transfusion purpura (PTP) is an extremely rare transfusion reaction in which the recipient has an anamnestic response with increased production of an anti-platelet alloantibody. This is similar to a DHTR, but the thrombocytopenia can be quite severe due to bystander destruction of the patient's own platelets that lack the alloantigen. Therapy is with high dose intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG); platelet transfusion may also be required for severe bleeding or severe bleeding risk. (See <a class="local">'Post-transfusion purpura'</a> above.)</p><p></p><p class="headingAnchor" id="H1900005258"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff gratefully acknowledges the extensive contributions of Arthur J. Silvergleid, MD, to earlier versions of this and many other topic reviews. </p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol. Centers for Disease Control and Prevention. Available at: www.cdc.gov/nhsn/pdfs/biovigilance/bv-hv-protocol-current.pdf (Accessed on December 06, 2021).</li><li><a class="nounderline abstract_t">Sapiano MRP, Savinkina AA, Ellingson KD, et al. Supplemental findings from the National Blood Collection and Utilization Surveys, 2013 and 2015. Transfusion 2017; 57 Suppl 2:1599.</a></li><li><a class="nounderline abstract_t">Chang CC, Lee TC, Su MJ, et al. Transfusion-associated adverse reactions (TAARs) and cytokine accumulations in the stored blood components: the impact of prestorage versus poststorage leukoreduction. Oncotarget 2018; 9:4385.</a></li><li><a class="nounderline abstract_t">Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. Blood 2019; 133:1831.</a></li><li><a class="nounderline abstract_t">Cohen R, Escorcia A, Tasmin F, et al. Feeling the burn: the significant burden of febrile nonhemolytic transfusion reactions. Transfusion 2017; 57:1674.</a></li><li><a class="nounderline abstract_t">Oakley FD, Woods M, Arnold S, Young PP. Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type, and associated products. Transfusion 2015; 55:563.</a></li><li><a class="nounderline abstract_t">Heddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol 1999; 6:420.</a></li><li><a class="nounderline abstract_t">Menis M, Forshee RA, Anderson SA, et al. Febrile non-haemolytic transfusion reaction occurrence and potential risk factors among the U.S. elderly transfused in the inpatient setting, as recorded in Medicare databases during 2011-2012. Vox Sang 2015; 108:251.</a></li><li><a class="nounderline abstract_t">Paglino JC, Pomper GJ, Fisch GS, et al. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004; 44:16.</a></li><li><a class="nounderline abstract_t">KEVY SV, SCHMIDT PJ, McGINNISS MH, WORKMAN WG. Febrile, nonhemolytic transfusion reactions and the limited role of leukoagglutinins in their etiology. Transfusion 1962; 2:7.</a></li><li><a class="nounderline abstract_t">Aubuchon JP, Dzik WS. Reports on clinical transfusion medicine in the early days of TRANSFUSION. Transfusion 2010; 50:963.</a></li><li><a class="nounderline abstract_t">BRITTINGHAM TE, CHAPLIN H Jr. Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets. J Am Med Assoc 1957; 165:819.</a></li><li><a class="nounderline abstract_t">Heddle NM, Klama LN, Griffith L, et al. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993; 33:794.</a></li><li><a class="nounderline abstract_t">Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994; 34:20.</a></li><li><a class="nounderline abstract_t">Mintz PD. Febrile reactions to platelet transfusions. Am J Clin Pathol 1991; 95:609.</a></li><li><a class="nounderline abstract_t">Cardigan R, Sutherland J, Garwood M, et al. The effect of leucocyte depletion on the quality of fresh-frozen plasma. Br J Haematol 2001; 114:233.</a></li><li><a class="nounderline abstract_t">Yomtovian R, Gernsheimer T, Assmann SF, et al. WBC reduction in RBC concentrates by prestorage filtration: multicenter experience. Transfusion 2001; 41:1030.</a></li><li><a class="nounderline abstract_t">Dzik WH, Anderson JK, O'Neill EM, et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002; 42:1114.</a></li><li><a class="nounderline abstract_t">Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999; 39:231.</a></li><li><a class="nounderline abstract_t">Azuma H, Hirayama J, Akino M, et al. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 2009; 49:214.</a></li><li><a class="nounderline abstract_t">Enright H, Davis K, Gernsheimer T, et al. Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 2003; 43:1545.</a></li><li><a class="nounderline abstract_t">Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994; 331:625.</a></li><li><a class="nounderline abstract_t">de Rie MA, van der Plas-van Dalen CM, Engelfriet CP, von dem Borne AE. The serology of febrile transfusion reactions. Vox Sang 1985; 49:126.</a></li><li><a class="nounderline abstract_t">Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A 2000; 97:6930.</a></li><li><a class="nounderline abstract_t">Zhang Y, Cao HJ, Graf B, et al. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol 1998; 160:1053.</a></li><li><a class="nounderline abstract_t">Phipps RP, Kaufman J, Blumberg N. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet 2001; 357:2023.</a></li><li><a class="nounderline abstract_t">Blumberg N, Gettings KF, Turner C, et al. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 2006; 46:1813.</a></li><li><a class="nounderline abstract_t">Sirchia G, Rebulla P, Parravicini A, et al. Leukocyte depletion of red cell units at the bedside by transfusion through a new filter. Transfusion 1987; 27:402.</a></li><li><a class="nounderline abstract_t">Ning S, Solh Z, Arnold DM, Morin PA. Premedication for the prevention of nonhemolytic transfusion reactions: a systematic review and meta-analysis. Transfusion 2019; 59:3609.</a></li><li><a class="nounderline abstract_t">Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion 2007; 47:1089.</a></li><li class="breakAll">Recommendations and licensure requirements for leukocyte-reduced blood products; May 29, 1996. Division of Blood Applications, Food and Drug Administration, Center for Biologics Evaluation and Research. Available at: www.fda.gov/cber/bldmem/mem52996.txt (Accessed on March 08, 2005).</li><li class="breakAll">http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm320636.htm (Accessed on March 04, 2014).</li><li><a class="nounderline abstract_t">Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002; 42:556.</a></li><li><a class="nounderline abstract_t">Yazer MH, Podlosky L, Clarke G, Nahirniak SM. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004; 44:10.</a></li><li><a class="nounderline abstract_t">King KE, Shirey RS, Thoman SK, et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004; 44:25.</a></li><li><a class="nounderline abstract_t">Kracalik I, Mowla S, Basavaraju SV, Sapiano MRP. Transfusion-related adverse reactions: Data from the National Healthcare Safety Network Hemovigilance Module - United States, 2013-2018. Transfusion 2021; 61:1424.</a></li><li><a class="nounderline abstract_t">Hirayama F. Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol 2013; 160:434.</a></li><li class="breakAll">Technical Manual, 20th ed, Cohn CS, Delaney M, Johnson ST, Katz LM (Eds), AABB, Bethesda 2020.</li><li><a class="nounderline abstract_t">Savage WJ, Tobian AA, Savage JH, et al. Scratching the surface of allergic transfusion reactions. Transfusion 2013; 53:1361.</a></li><li><a class="nounderline abstract_t">Savage WJ, Tobian AA, Savage JH, et al. Transfusion and component characteristics are not associated with allergic transfusion reactions to apheresis platelets. Transfusion 2015; 55:296.</a></li><li><a class="nounderline abstract_t">Savage WJ, Tobian AA, Savage JH, et al. Atopic predisposition of recipients in allergic transfusion reactions to apheresis platelets. Transfusion 2011; 51:2337.</a></li><li><a class="nounderline abstract_t">Apter AJ, Kaplan AA. An approach to immunologic reactions associated with plasma exchange. J Allergy Clin Immunol 1992; 90:119.</a></li><li><a class="nounderline abstract_t">Arnold DM, Blajchman MA, Ditomasso J, et al. Passive transfer of peanut hypersensitivity by fresh frozen plasma. Arch Intern Med 2007; 167:853.</a></li><li><a class="nounderline abstract_t">Savage WJ, Savage JH, Tobian AA, et al. Allergic agonists in apheresis platelet products are associated with allergic transfusion reactions. Transfusion 2012; 52:575.</a></li><li><a class="nounderline abstract_t">Savage WJ, Tobian AA, Fuller AK, et al. Allergic transfusion reactions to platelets are associated more with recipient and donor factors than with product attributes. Transfusion 2011; 51:1716.</a></li><li><a class="nounderline abstract_t">Tobian AA, Fuller AK, Uglik K, et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion 2014; 54:1523.</a></li><li><a class="nounderline abstract_t">Kacker S, Ness PM, Savage WJ, et al. The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions. Transfusion 2013; 53:2609.</a></li><li><a class="nounderline abstract_t">Silvergleid AJ, Hafleigh EB, Harabin MA, et al. Clinical value of washed-platelet concentrates in patients with non-hemolytic transfusion reactions. Transfusion 1977; 17:33.</a></li><li><a class="nounderline abstract_t">Buck SA, Kickler TS, McGuire M, et al. The utility of platelet washing using an automated procedure for severe platelet allergic reactions. Transfusion 1987; 27:391.</a></li><li><a class="nounderline abstract_t">Tobian AA, Savage WJ, Tisch DJ, et al. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion 2011; 51:1676.</a></li><li><a class="nounderline abstract_t">Karafin M, Fuller AK, Savage WJ, et al. The impact of apheresis platelet manipulation on corrected count increment. Transfusion 2012; 52:1221.</a></li><li><a class="nounderline abstract_t">Kennedy LD, Case LD, Hurd DD, et al. A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion 2008; 48:2285.</a></li><li><a class="nounderline abstract_t">Wang SE, Lara PN Jr, Lee-Ow A, et al. Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial. Am J Hematol 2002; 70:191.</a></li><li><a class="nounderline abstract_t">Wang JS, Sackett DJ, Yuan YM. [Randomized clinical controlled cross-over trial (RCT) in the prevention of blood transfusion febrile reactions with small dose hydrocortisone versus anti-histamines]. Zhonghua Nei Ke Za Zhi 1992; 31:536.</a></li><li><a class="nounderline abstract_t">Martí-Carvajal AJ, Solà I, González LE, et al. Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. Cochrane Database Syst Rev 2010; :CD007539.</a></li><li><a class="nounderline abstract_t">Bjerrum OJ, Gersild C. Class-specific anti-IgA associated with severe anaphylactic transfusion reactions in a patient with pernicious anemia. Vox Sang 1971; 21:411.</a></li><li><a class="nounderline abstract_t">Pineda AA, Taswell HF. Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature. Transfusion 1975; 15:10.</a></li><li><a class="nounderline abstract_t">Koda Y, Watanabe Y, Soejima M, et al. Simple PCR detection of haptoglobin gene deletion in anhaptoglobinemic patients with antihaptoglobin antibody that causes anaphylactic transfusion reactions. Blood 2000; 95:1138.</a></li><li><a class="nounderline abstract_t">Shimada E, Tadokoro K, Watanabe Y, et al. Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. Transfusion 2002; 42:766.</a></li><li><a class="nounderline abstract_t">Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion 1989; 29:124.</a></li><li class="breakAll">Reuther PA. Plasma exchange therapy in neurological disorders: a clinician's overview. In: Therapeutic Hemapheresis, MacPherson JL, Kasprisin DO (Eds), CRC Press, Boca Raton 1985. p.27.</li><li><a class="nounderline abstract_t">Leitman SF, Boltansky H, Alter HJ, et al. Allergic reactions in healthy plateletpheresis donors caused by sensitization to ethylene oxide gas. N Engl J Med 1986; 315:1192.</a></li><li><a class="nounderline abstract_t">Abe T, Matsumoto C, Shimada E, et al. Immunoglobulin E oligomers identified in blood components activate mast cells: relevance to anaphylactic transfusion reaction. Transfusion 2011; 51:2327.</a></li><li><a class="nounderline abstract_t">Jacobs JF, Baumert JL, Brons PP, et al. Anaphylaxis from passive transfer of peanut allergen in a blood product. N Engl J Med 2011; 364:1981.</a></li><li><a class="nounderline abstract_t">Anani W, Dobrozsi S, Punzalan R. Identification of Peanut allergen in a transfused blood product causing transfusion associated anaphylaxis. Transfusion 2020; 60:1108.</a></li><li><a class="nounderline abstract_t">Tinegate H, Birchall J, Gray A, et al. Guideline on the investigation and management of acute transfusion reactions. Prepared by the BCSH Blood Transfusion Task Force. Br J Haematol 2012; 159:143.</a></li><li><a class="nounderline abstract_t">McGonigle AM, Patel EU, Waters KM, et al. Solvent detergent treated pooled plasma and reduction of allergic transfusion reactions. Transfusion 2020; 60:54.</a></li><li><a class="nounderline abstract_t">Sandler SG. How I manage patients suspected of having had an IgA anaphylactic transfusion reaction. Transfusion 2006; 46:10.</a></li><li><a class="nounderline abstract_t">Vassallo RR. Review: IgA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgA-deficient products. Immunohematology 2004; 20:226.</a></li><li><a class="nounderline abstract_t">Thibault L, Beauséjour A, de Grandmont MJ, et al. Establishment of an immunoglobulin A-deficient blood donor registry with a simple in-house screening enzyme-linked immunosorbent assay. Transfusion 2006; 46:2115.</a></li><li><a class="nounderline abstract_t">Davenport RD. Pathophysiology of hemolytic transfusion reactions. Semin Hematol 2005; 42:165.</a></li><li class="breakAll">National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol. Centers for Disease Control and Prevention. Available at: www.cdc.gov/nhsn/pdfs/biovigilance/bv-hv-protocol-current.pdf (Accessed on December 22, 2021).</li><li><a class="nounderline abstract_t">Brand A. Immunological complications of blood transfusions. Presse Med 2016; 45:e313.</a></li><li><a class="nounderline abstract_t">Hawkins J, Aster RH, Curtis BR. Post-Transfusion Purpura: Current Perspectives. J Blood Med 2019; 10:405.</a></li><li><a class="nounderline abstract_t">Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013; 163:303.</a></li><li><a class="nounderline abstract_t">Mueller-Eckhardt C. Post-transfusion purpura. Br J Haematol 1986; 64:419.</a></li><li><a class="nounderline abstract_t">McCrae KR, Herman JH. Posttransfusion purpura: two unusual cases and a literature review. Am J Hematol 1996; 52:205.</a></li><li><a class="nounderline abstract_t">Vogelsang G, Kickler TS, Bell WR. Post-transfusion purpura: a report of five patients and a review of the pathogenesis and management. Am J Hematol 1986; 21:259.</a></li><li><a class="nounderline abstract_t">Ramsey G, Salamon DJ. Frequency of PLA1 in blacks. Transfusion 1986; 26:531.</a></li><li><a class="nounderline abstract_t">Pavenski K, Webert KE, Goldman M. Consequences of transfusion of platelet antibody: a case report and literature review. Transfusion 2008; 48:1981.</a></li><li><a class="nounderline abstract_t">Legler TJ, Köhler M, Mayr WR, et al. Genotyping of the human platelet antigen systems 1 through 5 by multiplex polymerase chain reaction and ligation-based typing. Transfusion 1996; 36:426.</a></li><li class="breakAll">https://www.versiti.org/medical-professionals/products-services/diagnostic-labs/5631 (Accessed on January 06, 2022).</li><li><a class="nounderline abstract_t">Mueller-Eckhardt C, Kiefel V. High-dose IgG for post-transfusion purpura-revisited. Blut 1988; 57:163.</a></li><li><a class="nounderline abstract_t">Becker T, Panzer S, Maas D, et al. High-dose intravenous immunoglobulin for post-transfusion purpura. Br J Haematol 1985; 61:149.</a></li><li><a class="nounderline abstract_t">Berney SI, Metcalfe P, Wathen NC, Waters AH. Post-transfusion purpura responding to high dose intravenous IgG: further observations on pathogenesis. Br J Haematol 1985; 61:627.</a></li><li><a class="nounderline abstract_t">Denomme G, Horsewood P, Xu W, et al. A simple and rapid competitive enzyme-linked immunosorbent assay to identify HPA-1a (PlA1)-negative donor platelet units. Transfusion 1996; 36:805.</a></li><li><a class="nounderline abstract_t">Gerstner JB, Smith MJ, Davis KD, et al. Posttransfusion purpura: therapeutic failure of PlAl-negative platelet transfusion. Am J Hematol 1979; 6:71.</a></li><li><a class="nounderline abstract_t">Taylor RW, O'Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med 2006; 34:2302.</a></li><li><a class="nounderline abstract_t">Michalopoulos A, Geroulanos S, Rosmarakis ES, Falagas ME. Frequency, characteristics, and predictors of microbiologically documented nosocomial infections after cardiac surgery. Eur J Cardiothorac Surg 2006; 29:456.</a></li><li><a class="nounderline abstract_t">Vamvakas EC, Carven JH. Exposure to allogeneic plasma and risk of postoperative pneumonia and/or wound infection in coronary artery bypass graft surgery. Transfusion 2002; 42:107.</a></li><li><a class="nounderline abstract_t">Vamvakas EC, Moore SB. Blood transfusion and postoperative septic complications. Transfusion 1994; 34:714.</a></li><li><a class="nounderline abstract_t">Murphy P, Heal JM, Blumberg N. Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions. Transfusion 1991; 31:212.</a></li><li><a class="nounderline abstract_t">Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993; 342:1328.</a></li><li><a class="nounderline abstract_t">Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97:1180.</a></li><li><a class="nounderline abstract_t">Llewelyn CA, Taylor RS, Todd AA, et al. The effect of universal leukoreduction on postoperative infections and length of hospital stay in elective orthopedic and cardiac surgery. Transfusion 2004; 44:489.</a></li><li><a class="nounderline abstract_t">Innerhofer P, Klingler A, Klimmer C, et al. Risk for postoperative infection after transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic patients undergoing primary arthroplasty. Transfusion 2005; 45:103.</a></li><li><a class="nounderline abstract_t">Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348:841.</a></li><li><a class="nounderline abstract_t">Weber WP, Zwahlen M, Reck S, et al. The association of preoperative anemia and perioperative allogeneic blood transfusion with the risk of surgical site infection. Transfusion 2009; 49:1964.</a></li><li><a class="nounderline abstract_t">Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79:513.</a></li><li><a class="nounderline abstract_t">Ottonello L, Ghio M, Contini P, et al. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I. Transfusion 2007; 47:1395.</a></li><li><a class="nounderline abstract_t">Vamvakas EC. WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials. Transfusion 2003; 43:963.</a></li><li><a class="nounderline abstract_t">Blumberg N. Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt. Transfusion 2005; 45:33S.</a></li><li><a class="nounderline abstract_t">Blumberg N, Zhao H, Wang H, et al. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion 2007; 47:573.</a></li></ol></div><div id="topicVersionRevision">Topic 7947 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.cdc.gov/nhsn/pdfs/biovigilance/bv-hv-protocol-current.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol. Centers for Disease Control and Prevention. Available at: www.cdc.gov/nhsn/pdfs/biovigilance/bv-hv-protocol-current.pdf (Accessed on December 06, 2021).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28591471" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Supplemental findings from the National Blood Collection and Utilization Surveys, 2013 and 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29435110" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Transfusion-associated adverse reactions (TAARs) and cytokine accumulations in the stored blood components: the impact of prestorage versus poststorage leukoreduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30808635" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Noninfectious transfusion-associated adverse events and their mitigation strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369916" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Feeling the burn: the significant burden of febrile nonhemolytic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25145580" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type, and associated products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10546797" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pathophysiology of febrile nonhemolytic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25470076" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Febrile non-haemolytic transfusion reaction occurrence and potential risk factors among the U.S. elderly transfused in the inpatient setting, as recorded in Medicare databases during 2011-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14692962" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14455460" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Febrile, nonhemolytic transfusion reactions and the limited role of leukoagglutinins in their etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19906039" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Reports on clinical transfusion medicine in the early days of TRANSFUSION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13462853" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8236418" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8273124" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cytokine generation in stored platelet concentrates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024621" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Febrile reactions to platelet transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11472374" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The effect of leucocyte depletion on the quality of fresh-frozen plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493735" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : WBC reduction in RBC concentrates by prestorage filtration: multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12430666" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A prospective, randomized clinical trial of universal WBC reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10204584" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18798806" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14617313" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8052271" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The role of the plasma from platelet concentrates in transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3898581" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The serology of febrile transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10860949" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9570516" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438137" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17002639" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3629670" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Leukocyte depletion of red cell units at the bedside by transfusion through a new filter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31670424" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Premedication for the prevention of nonhemolytic transfusion reactions: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17524101" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Transfusion premedications: a growing practice not based on evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17524101" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Transfusion premedications: a growing practice not based on evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17524101" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Transfusion premedications: a growing practice not based on evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12084163" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14692961" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14692963" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33880771" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Transfusion-related adverse reactions: Data from the National Healthcare Safety Network Hemovigilance Module - United States, 2013-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23215650" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23215650" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22998777" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Scratching the surface of allergic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25209730" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Transfusion and component characteristics are not associated with allergic transfusion reactions to apheresis platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21569041" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Atopic predisposition of recipients in allergic transfusion reactions to apheresis platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1629498" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : An approach to immunologic reactions associated with plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452551" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Passive transfer of peanut hypersensitivity by fresh frozen plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21883267" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Allergic agonists in apheresis platelet products are associated with allergic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21214586" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Allergic transfusion reactions to platelets are associated more with recipient and donor factors than with product attributes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24251374" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23363552" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/841669" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical value of washed-platelet concentrates in patients with non-hemolytic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3629668" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The utility of platelet washing using an automated procedure for severe platelet allergic reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21214585" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22233358" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The impact of apheresis platelet manipulation on corrected count increment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18673350" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12111764" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1303845" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : [Randomized clinical controlled cross-over trial (RCT) in the prevention of blood transfusion febrile reactions with small dose hydrocortisone versus anti-histamines].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20556779" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Class-specific anti-IgA associated with severe anaphylactic transfusion reactions in a patient with pernicious anemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1114508" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10666182" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Simple PCR detection of haptoglobin gene deletion in anhaptoglobinemic patients with antihaptoglobin antibody that causes anaphylactic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12147031" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2919422" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Complications of plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2919422" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Complications of plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2429183" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Allergic reactions in healthy plateletpheresis donors caused by sensitization to ethylene oxide gas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21470237" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Immunoglobulin E oligomers identified in blood components activate mast cells: relevance to anaphylactic transfusion reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21591965" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Anaphylaxis from passive transfer of peanut allergen in a blood product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32421872" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Identification of Peanut allergen in a transfused blood product causing transfusion associated anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22928769" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Guideline on the investigation and management of acute transfusion reactions. Prepared by the BCSH Blood Transfusion Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31840276" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Solvent detergent treated pooled plasma and reduction of allergic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16398725" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : How I manage patients suspected of having had an IgA anaphylactic transfusion reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15679454" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Review: IgA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgA-deficient products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17176323" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Establishment of an immunoglobulin A-deficient blood donor registry with a simple in-house screening enzyme-linked immunosorbent assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16041666" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pathophysiology of hemolytic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16041666" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pathophysiology of hemolytic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27499223" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Immunological complications of blood transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31849555" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Post-Transfusion Purpura: Current Perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24032719" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3790444" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Post-transfusion purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8756089" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Posttransfusion purpura: two unusual cases and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3946408" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Post-transfusion purpura: a report of five patients and a review of the pathogenesis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3775837" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Frequency of PLA1 in blacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18564398" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Consequences of transfusion of platelet antibody: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8693507" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Genotyping of the human platelet antigen systems 1 through 5 by multiplex polymerase chain reaction and ligation-based typing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8693507" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Genotyping of the human platelet antigen systems 1 through 5 by multiplex polymerase chain reaction and ligation-based typing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3139110" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : High-dose IgG for post-transfusion purpura-revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4052323" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : High-dose intravenous immunoglobulin for post-transfusion purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4084453" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Post-transfusion purpura responding to high dose intravenous IgG: further observations on pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823455" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A simple and rapid competitive enzyme-linked immunosorbent assay to identify HPA-1a (PlA1)-negative donor platelet units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/572138" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Posttransfusion purpura: therapeutic failure of PlAl-negative platelet transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16849995" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Red blood cell transfusions and nosocomial infections in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16481186" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Frequency, characteristics, and predictors of microbiologically documented nosocomial infections after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896321" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Exposure to allogeneic plasma and risk of postoperative pneumonia and/or wound infection in coronary artery bypass graft surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8073491" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Blood transfusion and postoperative septic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2003322" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7901637" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11222359" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15043563" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The effect of universal leukoreduction on postoperative infections and length of hospital stay in elective orthopedic and cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647025" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Risk for postoperative infection after transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic patients undergoing primary arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8826808" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453989" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The association of preoperative anemia and perioperative allogeneic blood transfusion with the risk of surgical site infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1611441" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17655583" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12823758" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16086785" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381614" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
